DEF 14A: Synaptogenix Seeks Stockholder Approval for Share Issuance, Director Elections, and Equity Plan Amendment at Upcoming Annual Meeting

Synaptogenix is holding its 2024 annual meeting of stockholders on December 6, 2024, to vote on director elections, a share issuance proposal, an equity incentive plan amendment, and ratification of the company's accounting firm.

Summary

• Synaptogenix, Inc. will hold its 2024 annual meeting of stockholders virtually on December 6, 2024, at 11:00 am Eastern Time.
• Stockholders will vote to elect two directors for three-year terms expiring in 2027.
• A key proposal involves authorizing the issuance of common stock underlying convertible preferred stock and warrants, related to a Securities Purchase Agreement dated September 10, 2024, potentially exceeding 20% of outstanding common stock.
• Stockholders will also vote on approving an amendment to the Synaptogenix, Inc. 2020 Equity Incentive Plan, increasing the number of shares available for grant by 500,000 shares.
• The meeting will also include a vote to ratify the appointment of Stephano Slack LLC as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The board of directors recommends voting in favor of the director nominees and each of the proposals.
• Stockholders of record as of November 5, 2024, are eligible to vote.
• The company intends to commence distribution of proxy materials to stockholders on or about November 8, 2024.

Sentiment

Score: 6

Explanation: The document is primarily informational, outlining the agenda for the annual meeting and seeking approval for routine corporate matters. The potential dilution from share issuance is a concern, but the overall tone is neutral.

Positives

• The company is seeking to increase the number of shares available under its equity incentive plan, which it believes is essential to attract, retain, and motivate key personnel.
• The board is recommending a vote FOR all proposals.

Negatives

• The issuance of shares related to the Securities Purchase Agreement could result in dilution for existing stockholders.
• If the Issuance Proposal is not approved, the company may be required to pay substantial cash amounts to the holders of the Series C Shares and Warrants, which it does not anticipate having sufficient funds to cover.

Risks

• Failure to approve the share issuance proposal could lead to insufficient funds to meet obligations to Series C Shares and Warrant holders.
• The potential issuance of Conversion Shares and Warrant Shares would result in an increase in the number of shares of common stock outstanding, and our stockholders will incur dilution of their percentage ownership to the extent that the Investors convert their Series C Shares or exercise their Warrants, or additional shares of common stock are issued pursuant to the anti-dilution terms of the Series C Shares or the Warrants.
• The increased number of issued shares could discourage the possibility of, or render more difficult, certain mergers, tender offers, proxy contests or other change of control or ownership transactions.

Future Outlook

The company is seeking stockholder approval to issue shares related to the September 10, 2024, Securities Purchase Agreement, which is crucial for securing additional funding and executing its business plan.

Management Comments

• The board of directors recommends a vote in favor of the two directors nominated for election and the approval of each of these proposals.
• Thank you for your continued support of the Company, said Alan J. Tuchman, M.D. Chief Executive Officer

Industry Context

This announcement is typical for publicly traded companies as they prepare for their annual meetings, seeking stockholder approval on key governance matters and strategic initiatives.

Comparison to Industry Standards

• The structure of the board of directors with classified terms is a common practice among publicly traded companies.
• The equity incentive plan is a standard tool used by companies to attract and retain talent.
• The need for stockholder approval for share issuances exceeding 20% is dictated by Nasdaq listing rules, ensuring shareholder protection against excessive dilution.
• The company's executive compensation arrangements appear to be in line with industry standards for similar-sized companies.

Related Party Transactions

• The company has a consulting agreement with SM Capital Management, LLC (SMCM), a limited liability company owned and controlled by the Company’s Chairman of the Board, Mr. Joshua N. Silverman.

Stakeholder Impact

• Approval of the share issuance proposal could result in dilution for existing stockholders.
• Approval of the equity incentive plan amendment could benefit employees, consultants, and directors through equity ownership.
• The outcome of the proposals will impact the company's financial position and ability to execute its business plan.

Next Steps

• Stockholders are urged to vote on the proposals outlined in the proxy statement.
• The company will hold its annual meeting on December 6, 2024, to conduct the business described in the proxy statement.

Key Dates

Keywords

annual meeting, proxy statement, stockholders, directors, share issuance, equity incentive plan, auditor ratification, Synaptogenix